Natco Pharma

Sept 28 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA- TO INCREASE ITS INVESTMENT IN EGENESIS FROM $14.00 MILLION TO $16.70 MILLION THROUGH ITS UNITS

Further company coverage: NATP.NS

(([email protected];))

Natco Pharma's board approved the terms of its rights issue on 25 September, setting the issue price at ₹750 per share and the entitlement at two rights shares for every 21 shares held. The issue comprised 1,70,58,082 equity shares aggregating to about ₹1,279.4 crore, with 1 October fixed as the record date and subscription scheduled from 12 to 22 October, including on-market renunciation until 16 October. The board approved a rights issue of up to ₹1,300 crore on 9 September and filed a draft letter of offer providing for ₹810.5 crore of debt repayment and ₹110 crore of research and development spending with the balance for inorganic and general corporate purposes. NSE and BSE granted in-principle approvals for the issue on 21 September. Consolidated total income was about ₹4,376 crore in FY26, with export formulations contributing about 74% and the company holding a 49% associate stake in Adcock Ingram in South Africa.

Powered by Tijori

Natco Pharma's board approved the terms of its rights issue to raise up to Rs 1,279.36 crore through the issuance of 1,70,58,082 equity shares at Rs 750 apiece. The shares were offered in the ratio of two rights shares for every 21 shares held, with 1 October fixed as the record date and the subscription window set for 12 to 22 October, including an on-market renunciation period until 16 October. The terms followed a draft letter of offer for up to Rs 1,300 crore filed on 9 September that earmarked Rs 810.5 crore for debt repayment and Rs 110 crore for research and development, with the balance for inorganic expansion and general corporate purposes. In-principle approvals from the NSE and the BSE were received on 21 September. Natco reported consolidated total income of Rs 4,375.9 crore in FY26, with export formulations accounting for about 74% of the mix, and held about Rs 1,400 crore of net cash after spending about Rs 1,600 crore to lift its holding in South African associate Adcock to 49%.

Powered by Tijori

Natco Pharma proposed a rights issue of up to ₹1,300 crore, while leaving the issue price, entitlement ratio and timetable unspecified. It earmarked ₹810.5 crore to repay borrowings and ₹110 crore for research and development, with the residual proceeds intended for unidentified acquisitions, strategic initiatives and general corporate purposes. Natco held a 49% stake in South Africa’s Adcock Ingram and operated nine manufacturing facilities and two research centres. Consolidated total income was ₹4,375.9 crore in the year ended March 2026, including ₹3,234.5 crore from export formulations.

Powered by Tijori

Natco Pharma's board approved a rights issue of fully paid equity shares to eligible shareholders to raise up to ₹1,300 crore, subject to regulatory approvals. The issue price, rights entitlement ratio and record date were left for later finalisation, while a fund-raising committee and draft letter of offer were approved. The proposed issue would require changes to the planned demerger of Natco Crop Health Sciences; the scheme had received observation letters from both stock exchanges but had not yet been filed with the National Company Law Tribunal. Natco had earlier been evaluating a fund raise of up to ₹2,000 crore. Consolidated revenue was ₹4,375.9 crore in FY26, while net cash stood at about ₹1,400 crore after spending on its Adcock Ingram investment.

Powered by Tijori

Sept 9 (Reuters) - Natco Pharma Ltd NATP.NS:

• APPROVES RIGHTS ISSUE OF EQUITY SHARES UP TO 13 BILLION RUPEES

Further company coverage: NATP.NS

(([email protected];))

Aug 25 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - INVESTING $14 MILLION IN EGENESIS, INC VIA UNITS

Source text: [ID:]

Further company coverage: NATP.NS

(([email protected];;))

Natco Pharma's board approved exploring a fund raise of up to ₹2,000 crore through equity shares or other securities, subject to shareholder and regulatory approvals. The proposal did not specify an instrument, pricing or use of proceeds. The company reported consolidated revenue of ₹794.4 crore and profit after tax of ₹206.5 crore for the quarter ended June 30, 2026, down from ₹1,390.6 crore and ₹480.3 crore respectively a year earlier. It attributed the decline mainly to lower lenalidomide revenue, partly offset by growth in its base business. The board declared an interim dividend of ₹1.50 per share. Natco's consolidated results included ₹84.3 crore of profit from its Adcock Ingram associate, whose revenue was ₹1,582.8 crore in the quarter. The group had about ₹2,400 crore of net cash and had recently increased its holding in Adcock Ingram to 49%.

Powered by Tijori

Aug 14 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - DECLARES Q1 FY27 INTERIM DIVIDEND OF 1.50 RUPEE PER EQUITY SHARE

• NATCO PHARMA - APPROVED FUND RAISING UP TO 20 BILLION RUPEES

Source text: ID:nBSE8C1768

Further company coverage: NATP.NS

(([email protected];))

Aug 11 (Reuters) - Natco Pharma Ltd NATP.NS:

• BOARD TO MEET ON AUGUST 14, 2026 TO CONSIDER FUND RAISING

• TO CONSIDER FUND RAISING VIA EQUITY OR OTHER SECURITIES

Source text: ID:nBSELkP58

Further company coverage: NATP.NS

(([email protected];))

** Drug maker Natco Pharma's shares NATP.NS rise as much as 4.5%, their sharpest intraday rise in two weeks, to 987.55 rupees apiece

** NATP last up 2.6%

** Rise after NATP receives tentative approval from the U.S. drug regulator for Olaparib, 100 mg and 150 mg, a bioequivalent to the reference listed drug (RLD) Lynparza tablets

** Olaparib, which is used to treat specific types of cancers, had estimated sales of $1.4 billion in the U.S for 12 months ending March 2026, NATP says in an exchange filing

** NATP shares are up 7.7% in 2026 so far, lagging the 15% rise in the pharma index .NIPHARM, exchange data shows

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Natco Pharma received tentative approval from the US Food and Drug Administration on July 18, 2026, for its generic version of AstraZeneca’s cancer drug Lynparza (olaparib) in 100 mg and 150 mg doses. Natco will manufacture the tablets, and its partner Alembic Pharmaceuticals will distribute the product in the US market. The brand drug had estimated US sales of approximately $1.4 billion for the twelve months ended March 2026, according to industry data. The approval is tentative because Paragraph IV patent litigation is ongoing, meaning Natco cannot launch the product until the legal process concludes or the patents expire. The FDA’s tentative nod confirms that the generic meets all quality, safety and efficacy standards, positioning Natco for a potential commercial launch if it prevails in court.

Powered by Tijori

Natco Pharma’s board on July 8, 2026, approved two major capital commitments in South Africa. The company will invest up to ₹1,400 crore in its wholly owned subsidiary, Natco Pharma South Africa Proprietary Limited, and, in a separate transaction, will acquire an additional 13.25 per cent stake in Adcock Ingram Holdings Proprietary Limited for about 1.8 billion South African rand (₹1,069 crore), taking its total holding to 49 per cent. Adcock Ingram, one of South Africa’s largest pharmaceutical companies with a leading over-the-counter portfolio, reported a topline of approximately $423 million for the nine months ended March 2026. The board approvals are subject to customary closing conditions and regulatory clearances in India and South Africa, with completion targeted before the end of July 2026.

Powered by Tijori

July 8 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - APPROVES INVESTMENT UP TO 14 BILLION RUPEES IN WHOLLY OWNED SUBSIDIARY IN SOUTH AFRICA

• NATCO PHARMA - BOARD APPROVES INCREASING STAKE IN ADCOCK INGRAM HOLDINGS TO 49%

Source text: ID:nBSE5hXgBn

Further company coverage: NATP.NS

(([email protected];))

May 29 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA MARCH-QUARTER CONSOL NET PROFIT 2.68 BILLION RUPEES

• NATCO PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 7.39 BILLION RUPEES

Source text: ID:nBSE8vJ6vT

Further company coverage: NATP.NS

(([email protected];))

May 15 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - GETS DEMAND OF 49.2 MILLION RUPEES FROM NATIONAL PHARMACEUTICAL PRICING AUTHORITY

Source text: ID:nBSE9tfp56

Further company coverage: NATP.NS

(([email protected];))

March 24 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - TO INCORPORATE WHOLLY OWNED SUBSIDIARY IN NIGERIA WITH INVESTMENT UP TO $100,000

• NATCO PHARMA - TO LIQUIDATE WHOLLY OWNED SUBSIDIARY IN AUSTRALIA

• NATCO PHARMA - BOARD APPROVES SCHEME OF ARRANGEMENT WITH NATCO CROP HEALTH SCIENCES

• NATCO PHARMA - CROP HEALTH SCIENCES TO ISSUE 1:1 SHARES TO NATCO PHARMA SHAREHOLDERS

Source text: ID:nNSE41gmTn

Further company coverage: NATP.NS

(([email protected];))

March 23 (Reuters) - At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's NOVOb.CO blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy over the weekend, at globally unmatched prices and slashing treatment costs by about 70%.

The patent for semaglutide, the active ingredient in Novo's drugs, expired in India last week, paving the way for drugmakers to flood the market with dozens of brands.

Analysts expect more than 40 Indian drugmakers to launch over 50 cheaper variants.

Large Indian drugmakers are racing to capture a share of the global obesity market, projected to be worth about $100 billion by the end of the decade. They are eyeing overseas markets, including Canada, Brazil, Latin America, and Turkey, for future launches.

Here is a list of Indian drugmakers that have launched generic semaglutide in recent days:

SUN PHARMACEUTICAL SUN.NS

India's largest drugmaker by revenue launched semaglutide injectable under the brand name Noveltreat for chronic weight management in five dose strengths from 0.25 mg to 2.4 mg and Sematrinity in two dose strengths for type 2 diabetes. Noveltreat is expected to cost around 900 to 2000 rupees ($9.58-$21.30) for weekly treatment, and Sematrinity will cost 750 to 1300 rupees ($7.99-$13.84), the company said.

DR REDDY'S LABORATORIES REDY.NS

The Hyderabad-based drugmaker launched semaglutide under the brand name Obeda for diabetes in 2 mg and 4 mg dose strengths in a disposable pen device format. Each pen of both strengths will deliver a minimum of four weekly doses and cost about 4200 rupees ($44.73) per month, the company said.

ZYDUS LIFESCIENCES ZYDU.NS

The company launched generic injectable semaglutide under three different brand names- Semaglyn, Mashema, and Alterme - for diabetes and obesity treatment in a reusable pen device. The average monthly cost of the treatment will be approximately 2,200 rupees ($23.43), the company said.

TORRENT PHARMACEUTICALS TORP.NS

The company launched an oral and injectable semaglutide drug under the brand names Sembolic and Semalix. The starting price for the injectable drugs would be 3,999 rupees ($42.59) per month, the company said.

GLENMARK PHARMACEUTICALS GLEN.NS

Glenmark launched injectable semaglutide, branded as GLIPIQ, in vial and pen formats for diabetes treatment. The vial is estimated to cost around 1,300 to 1,760 rupees for a month's usage. ($13.84-$18.74).

ALKEM LABORATORIES ALKE.NS

The company said its semaglutide, launched under three brand names - Semasize, Obesema, and Hepaglide - will be available in a pre-filled disposable injection pen and cost starting at 1,800 rupees ($19.17) per month.

ERIS LIFESCIENCES ERIS.NS

The company launched generic semaglutide in a vial format named 'Sundae.' The starting price for the multi-dose vials is 1,290 rupees ($13.74) per month. Eris is also in partnership with Natco Pharma NATP.NS, which has also launched its own generic semaglutide, for commercial manufacturing of the drug.

($1 = 93.9000 Indian rupees)

(Reporting by Rishika Sadam; Editing by Rashmi Aich)

(([email protected];))

March 20 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - LAUNCHES SEMAGLUTIDE GENERIC INJECTION MULTI DOSE VIALS IN INDIA

• NATCO PHARMA - MULTI DOSE VIALS LAUNCHED AT 1,290 RUPEES AND 1,750 RUPEES PER MONTH

• NATCO PHARMA - PEN DEVICE PRICED AT 4,000 RUPEES AND 4500 RUPEES PER MONTH, LAUNCH EXPECTED APRIL 2026

Source text: ID:nNSE2S1pW8

Further company coverage: NATP.NS

(([email protected];))

March 18 (Reuters) - Natco Pharma Ltd NATP.NS:

• BOARD TO CONSIDER DEMERGER OF AGROCHEMICALS DIVISION

Source text: ID:nBSEtvJ4y

Further company coverage: NATP.NS

(([email protected];))

March 3 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - LAUNCHES POMALIDOMIDE CAPSULES IN U.S. MARKET

Source text: ID:nNSEHZsrg

Further company coverage: NATP.NS

(([email protected];))

March 3 (Reuters) - Breckenridge Pharmaceutical:

• BRECKENRIDGE PHARMACEUTICAL- BRECKENRIDGE LAUNCHES POMALIDOMIDE CAPSULES

• BRECKENRIDGE PHARMACEUTICAL-POMALIDOMIDE CAPSULES AVAILABLE ONLY THROUGH PS-POMALIDOMIDE REMS PROGRAM

Source text: ID:nPn4Q6sTZa

(([email protected];))

Feb 25 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - COMPANY TO LAUNCH SEMAGLUTIDE IN INDIA IN MARCH 2026

Source text: ID:nBSE4rCg7D

Further company coverage: NATP.NS

(([email protected];))

Feb 24 (Reuters) - Eris Lifesciences Ltd ERIS.NS:

• ANNOUNCES STRATEGIC PARTNERSHIP WITH NATCO PHARMA FOR SEMAGLUTIDE LAUNCH IN INDIA

Further company coverage: ERIS.NS

(([email protected];;))

** Natco Pharma NATP.NS jumps ~11% to 913 rupees

** Pharma co gets Indian drug regulator's approval to manufacture and market generic semaglutide injection in country; injection used to treat type-2 diabetes mellitus, manage weight

** Product launch likely in March

** Trading volume at more than 8x the 30-day average

** YTD, NATP up ~1% vs ~2% fall in Nifty 500 index .NIFTY500

(Reporting by Vijay Malkar)

(([email protected];))

Feb 13 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - API UNIT IN CHENNAI RECEIVES ESTABLISHMENT INSPECTION REPORT FROM U.S. FDA

• NATCO PHARMA - API UNIT IN CHENNAI RECEIVES EIR FROM U.S. FDA

• NATCO PHARMA - COMPANY RECEIVED SEVEN OBSERVATIONS

• NATCO PHARMA - RECEIVED EIR CLASSIFIED AS VOLUNTARY ACTION INDICATED

Source text: ID:nBSEM8T3j

Further company coverage: NATP.NS

(([email protected];))

Feb 12 (Reuters) - Natco Pharma Ltd NATP.NS:

• DEC-QUARTER CONSOL NET PROFIT 1.52 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 6.47 BILLION RUPEES

• RE-APPOINTMENT OF RAJEEV NANNAPANENI AS CEO

• DECLARED DIVIDEND OF RS. 1.50 RUPEES PER SHARE

• RE-APPOINTMENT OF VENKAIAH CHOWDARY NANNAPANENI AS CHAIRMAN & MANAGING DIRECTOR

Further company coverage: NATP.NS

(([email protected];))

Feb 3 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - RECEIVES TENTATIVE APPROVAL FOR ERDAFITINIB TABLETS

Source text: ID:nBSE19q71R

Further company coverage: NATP.NS

(([email protected];;))

Jan 30 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - NATCO PHARMA ASIA BUYS 49% OF PT NATCO LOTUS FARMA FROM PT LOTUS FARMA INDONESIA

• NATCO PHARMA - COST OF ACQUISITION IS ABOUT 77 MILLION RUPEES

Source text: ID:nNSEW2yQ3

Further company coverage: NATP.NS

(([email protected];))

** Natco Pharma NATP.NS rises 3.3% to 840 rupees

** Delhi Court dismisses appeal filed against co by F. Hoffmann-La Roche AG over launch of Risdiplam drug in India

** Judgment paves way for co to launch generic version of drug 'Risdiplam', used to treat spinal muscular atrophy

** Co to launch product with immediate effect at 15,900 rupees; offer some discount to certain deserving patients through its patient access programme

** Around 2.2 mln shares traded, more than 5x the 30-day avg

** YTD, NATP falls ~39%

(Reporting by Vijay Malkar)

(([email protected];))